IQVIA Holdings Inc (IQV)vsNeoGenomics Inc (NEO)
IQV
IQVIA Holdings Inc
$261.77
+1.74%
HEALTHCARE · Cap: $42.24B
NEO
NeoGenomics Inc
$17.32
-1.65%
HEALTHCARE · Cap: $2.27B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 2116% more annual revenue ($16.98B vs $766.29M). IQV leads profitability with a 8.1% profit margin vs -6.8%. IQV appears more attractively valued with a PEG of 0.97. IQV earns a higher WallStSmart Score of 55/100 (C).
IQV
Buy55
out of 100
Grade: C
NEO
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+11.9%
Fair Value
$201.21
Current Price
$261.77
$60.56 discount
Margin of Safety
+78.2%
Fair Value
$52.45
Current Price
$17.32
$35.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Earnings expanding 130.6% YoY
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 0.6%
Distress zone — elevated risk
Expensive relative to growth rate
Weak financial health signals
ROE of -12.0% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : NEO
The strongest argument for NEO centers on EPS Growth, Price/Book. Revenue growth of 11.2% demonstrates continued momentum.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Bear Case : NEO
The primary concerns for NEO are PEG Ratio, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
IQV profiles as a value stock while NEO is a turnaround play — different risk/reward profiles.
NEO carries more volatility with a beta of 1.75 — expect wider price swings.
NEO is growing revenue faster at 11.2% — sustainability is the question.
IQV generates stronger free cash flow (360M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (55/100 vs 48/100). NEO offers better value entry with a 78.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
NeoGenomics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?